活动性氧疗对纤维化间质性肺病伴孤立性运动低氧血症的客观效果与患者偏好:安慰剂对照6分钟步行试验研究
本研究为随机双盲安慰剂对照交叉试验,纳入32例静息血氧正常的纤维化间质性肺病患者,均在基线6分钟步行试验中血氧饱和度降至≤88%。患者以个人化氧流量分别接受氧气和安慰剂(压缩医用空气)完成两次6分钟步行试验。结果显示活动性氧疗较安慰剂可防止血氧下降、减轻心动过速、增加步行距离37米(95%CI:10-74,p=0.008),并减轻呼吸困难和疲劳;患者对氧气的偏好显著优于安慰剂,但对氧气与室内空气的偏好无显著差异。
要点
- 活动性氧疗较安慰剂增加纤维化间质性肺病患者6分钟步行距离37米(95%CI:10-74,p=0.008)。
- 活动性氧疗可防止运动性血氧下降、减轻心动过速、呼吸困难和疲劳。
- 患者对氧气的偏好显著优于安慰剂,但部分患者对氧气有负面感知,可能影响治疗接受度。
核心结论
- 活动性氧疗在纤维化间质性肺病伴孤立性运动低氧血症患者中提供的获益超出安慰剂效应。
- 部分患者对活动性氧疗存在负面感知,可能阻碍治疗接受,建议将6分钟步行试验时记录的患者偏好纳入临床讨论以辅助共享决策。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,纳入32例静息血氧正常的纤维化间质性肺病患者,基线6分钟步行试验中血氧饱和度降至≤88%。
- 在确定防止血氧下降所需氧流量后,患者以相同个人化流量分别完成氧气和安慰剂(压缩医用空气)两次双盲6分钟步行试验。
主要发现
- 活动性氧疗较安慰剂防止血氧下降、减轻心动过速、增加步行距离37米(95%CI:10-74,p=0.008),并减轻呼吸困难和疲劳。
- 患者对氧气相较于安慰剂的平均偏好评分为2.6(95%CI:1.9-3.2,p<0.0005),显著高于等效值。
- 患者对安慰剂相较于室内空气的偏好评分为-1.5(95%CI:-2.4至0.64,p=0.005),显著低于等效值。
- 患者对氧气相较于室内空气的偏好评分为0.4(95%CI:-0.7至1.5),与等效值无显著差异。
临床怎么用
- 活动性氧疗可改善纤维化间质性肺病伴孤立性运动低氧血症患者的运动表现和症状,证据支持当前推荐。
- 临床讨论中可纳入6分钟步行试验时记录的患者偏好,以辅助活动性氧疗的共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The available evidence on the effects of ambulatory oxygen on exercise impairment in patients with fibrotic interstitial lung diseases (F-ILD) is of limited quality. METHODS: We conducted a randomised, double-blind, placebo-controlled crossover trial with 32 normoxaemic F-ILD patients, desaturating to ≤ 88% during a baseline 6-minute walk test (6MWT) on ambient air. After determining the oxygen flow needed to prevent desaturation, patients completed two double-blind 6MWTs with either oxygen or placebo (compressed medical air) at the same personalised flow. Objective measures included oxygen saturation, pulse rate, and distance walked. Patient-reported outcomes, assessed via visual analogue scales, included end-of-test dyspnoea, fatigue, and preferences for walking with oxygen or placebo versus each other and ambient air. RESULTS: Ambulatory oxygen, compared to placebo, prevented desaturation, reduced tachycardia, increased walking distance by 37 m (95% CI: 10-74, p = 0.008), and lessened dyspnoea and fatigue. The mean preference score for oxygen over placebo was 2.6 (95% CI: 1.9-3.2, p < 0.0005), significantly greater than equivalence. The preference score for placebo over ambient air was -1.5 (-2.4 to 0.64, p = 0.005), significantly lower than equivalence, while the score for oxygen over ambient air was 0.4 (-0.7 to 1.5), not significantly different from equivalence. CONCLUSIONS: Our data confirm that ambulatory oxygen provides significant benefits beyond a placebo effect; although in some patients it is associated with a negative perception that may hinder treatment acceptance. This strengthens the evidence supporting current recommendations and suggests that incorporating patient preferences recorded at the time of the 6MWT into clinical discussions can aid shared decision making regarding ambulatory oxygen. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02668029.
引用
- Ciarleglio G, Cameli P, Bennett D, et al. Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo-Controlled 6-Minute Walk Test Study. Respirology. 2025. PMID: 40069946. doi:10.1111/resp.70020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。